Pharmacyclics — a subsidiary of the global biopharmaceutical company AbbVie — earned expanded approval for its drug Imbruvica from the Food and Drug Administration Wednesday.
Here are three things to know.
1. The FDA previously approved Imbruvica for the treatment of lymphocytic leukemia.
2. Under the expanded approval, the drug can be used to treat adult patients with chronic graft versus host disease, which occurs when immune cells from donated tissues — often stem cells from donated bone marrow — attack the new host's body cells.
3. Imbruvica is the first FDA-approved therapy for the treatment of chronic graft versus host disease.
More articles on supply chain:
Senate passes FDA user fee reauthorization bill
6 must-reads for supply chain leaders this week
Express Scripts adds 64 drugs to exclusion list